论文部分内容阅读
本文应用CA-125 IRMA检测562例患者(其中232例恶性肿瘤、330例良性疾病患者)血清CA-125水平进行回顾性分析,旨在对血清CA-125测定的临床意义有更进一步了解和认识。 对象和方法 一、对象: (一)病例组:选择1995年1月～1997年5月在本院住院,经病史、临床表现、B超、Ⅹ线、CT、内窥镜、病理、实验室检查等确诊的病人,并经血清CA-125检测。其中男179例,平均年龄48.6岁;女383例,平均年龄45.5岁。 (二)正常对照组:40例(男20例,女20例),年龄20～58岁,平均36岁。选自本院健康体检合格的正常人,均无心、肝、脾、肺、肾、妇科等重要脏器疾病,肝、肾功能试验正常。 二、方法:CA-125 IRMA试剂盒由天津德普公司提供,正常参考值<35U/ml,标准品范围0～1500U/ml,按说明书操作。仪器为北京核仪器厂生产的FT-630G微机多探头γ计数器。 结果 一、40例正常对照检测结果为16.8±7.4U/ml,本文以>35U/ml为阳性界限。正常对照组40例均<35U/ml,为阴性。 二、本文检测住院患者562例(恶性肿瘤232例,占总例数的41.3％;良性疾病330例,占总例数的58.7％）,详见表1～2。
In this paper, CA-125 IRMA was used to detect the level of serum CA-125 in 562 patients (including 232 malignant tumors and 330 benign diseases). The aim of this study was to further understand and understand the clinical significance of serum CA-125 . Subjects and methods First, the object: (a) case group: choose January 1995 to May 1997 in our hospital, medical history, clinical manifestations, B-, CT, endoscopy, pathology, laboratory Check and other diagnosed patients, and detected by serum CA-125. There were 179 males, with an average age of 48.6 years and 383 females, with an average age of 45.5 years. (B) normal control group: 40 cases (20 males and 20 females), aged 20 to 58 years, mean 36 years old. Normal subjects selected from the health examination in our hospital are not heart, liver, spleen, lung, kidney, gynecology and other important organ diseases, liver and kidney function test is normal. Second, the method: CA-125 IRMA kit provided by the Tianjin Depp, the normal reference value <35U / ml, standard range 0 ~ 1500U / ml, according to instructions. Instruments for the Beijing Nuclear Instrument Factory FT-630G microcomputer multi-probe γ counter. Results one, 40 cases of normal control test results for 16.8 ± 7.4U / ml, this article to> 35U / ml as the positive limit. The normal control group, 40 cases were <35U / ml, was negative. Second, this article examines 562 inpatients (232 cases of malignant tumors, accounting for 41.3% of the total number of cases; 330 cases of benign diseases, accounting for 58.7% of the total), as shown in Table 1 ~ 2.